supplementNot FDA-approvedOTC supplementNot FDA-approved as a drug in the US; marketed domestically as a dietary supplement, while it is a prescription medicine in several other countriesThe Cochrane review found the evidence base too limited in size and quality to draw firm conclusions about efficacy for dementia or cognitive impairment
VinpocetineBenefits, Dosage & Interactions
Vinpocetine is a synthetic ethyl ester of apovincamine, an alkaloid derived from the Vinca minor plant, commonly known as periwinkle. It was first synthesized in the late 1960s. Research on Vinpocetine focuses on cognition and mood. It is typically taken in the morning.
How much Vinpocetine do people take?
Cochrane review covered trials using roughly 30 mg/day oral vinpocetine; other clinical and cognitive-enhancer literature cites doses in a similar 15–60 mg/day range. Route reported: Oral, as tablets in the trials reviewed. Frequency reported: Divided into multiple daily doses (typically two to three times daily) in the reviewed trials. These are amounts documented in the cited studies and labels for Vinpocetine — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
See the full reported protocol and its sourcesResearched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.
Evidence: Strong — 1 human randomized trial published.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence
1 human randomized trial published.
Plasma half-life
Not applicable
Typical timing
in the morning
Food rule
with food
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- Cochrane review covered trials using roughly 30 mg/day oral vinpocetine; other clinical and cognitive-enhancer literature cites doses in a similar 15–60 mg/day range[1][2]
Reported for Vinpocetine in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Vinpocetine entry is written from. Each number matches an inline marker above.
- [1]Vinpocetine for cognitive impairment and dementiaSzatmari SZ, Whitehouse PJ · Cochrane Database of Systematic Reviews · 2003 · Peer-reviewed · PMID 12535455
- [2]Vinpocetine, cognition, and epilepsyMeador KJ, Leeman-Markowski B, Medina AE, Illamola SM, Seliger J, Novak G · Epilepsy & Behavior · 2021 · Peer-reviewed · PMID 33957389
- [3]The Use and Impact of Cognitive Enhancers among University Students: A Systematic ReviewSharif S, Guirguis A, Fergus S, Schifano F · Brain Sciences · 2021 · Peer-reviewed · PMID 33802176
References & Evidence
Sources on this page that document Vinpocetine dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Vinpocetine studied for?
What is Vinpocetine?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Vinpocetine is a synthetic ethyl ester of apovincamine, an alkaloid derived from the *Vinca minor* plant, commonly known as periwinkle. It was first synthesized in the late 1960s. Historically, it has been investigated for its potential effects on cerebral blood flow and cognitive function. In some regions, it is available as a prescription medication, while in others, it is sold as a dietary supplement. Interest in vinpocetine stems from its purported ability to support brain health, particularly in areas related to memory and focus. (Examine.com, PubChem)
What does the research say about Vinpocetine?
Tap a section to expand.
Vinpocetine is thought to exert its effects through multiple biochemical pathways. One primary proposed mechanism involves its action as a phosphodiesterase type 1 (PDE1) inhibitor. By inhibiting PDE1, vinpocetine may lead to increased intracellular levels of cyclic guanosine monophosphate (cGMP) in smooth muscle cells, which can result in vasodilation, particularly in cerebral blood vessels. This effect is hypothesized to enhance cerebral blood flow. (DrugBank, PubChem)
Additionally, vinpocetine is believed to possess neuroprotective properties. Research suggests it may modulate voltage-dependent sodium channels and calcium channels, which could contribute to its ability to protect neurons from damage under ischemic conditions. It may also interfere with adenosine reuptake and inhibit platelet aggregation, further supporting its potential role in improving microcirculation. Some studies suggest it has antioxidant properties, helping to counteract oxidative stress within the brain. (DrugBank)
Source for this section: Sources for How does Vinpocetine work?: Jumps to this entry in the sources and references list at the end of the page.
- **Cognitive Function:** Vinpocetine has been studied for its potential to support various aspects of cognitive function, including memory, attention, and executive functions. Some research indicates that it may help improve these parameters, particularly in contexts where cerebral blood flow or neuronal health is compromised. (Cochrane Review, Examine.com)
- **Cerebral Blood Flow:** A key area of investigation for vinpocetine is its potential to increase blood flow to the brain. By dilating cerebral blood vessels, it is hypothesized to deliver more oxygen and nutrients to brain tissue. This increased perfusion is often cited as a mechanism for its observed cognitive effects. (Examine.com)
- **Neuroprotection:** Experimental studies have explored vinpocetine's capacity to protect brain cells from various forms of damage, including that caused by ischemia (insufficient blood flow) or oxidative stress. This neuroprotective action is attributed to its multifaceted mechanisms, including antioxidant activity and modulation of ion channels. (DrugBank)
Evidence for vinpocetine's benefits in human health is derived from a range of studies, though the quality and consistency of findings vary. A Cochrane review examining vinpocetine for dementia and cognitive impairment noted some positive outcomes in various cognitive measures, but the studies reviewed often had methodological limitations, and larger, more robust trials are needed to draw definitive conclusions. (Cochrane Review)
Numerous animal and *in vitro* studies support the proposed mechanisms, such as increased cerebral blood flow and neuroprotective effects. In human trials, some studies have indicated improvements in memory and concentration in individuals with age-related cognitive decline or cerebrovascular disorders. For instance, research published in peer-reviewed journals has often explored its use in post-stroke recovery or in individuals with mild cognitive impairment, with mixed but sometimes encouraging results regarding symptom management and cognitive performance. (Examine.com, PubChem)
It is important to acknowledge that while some evidence suggests potential benefits, particularly in specific populations or conditions, regulatory bodies in different countries have varying stances on its efficacy and safety. For example, in the United States, concerns have been raised regarding its classification as a dietary ingredient by the FDA due to its synthetic nature and history as a drug. This difference in classification reflects the ongoing debate regarding the interpretation of available scientific evidence. (FDA Statement)
Commonly reported side effects of vinpocetine are generally mild and may include digestive upset such as nausea, indigestion, and dry mouth. Other potential side effects involve headaches, dizziness, and flushing. In some individuals, blood pressure changes, including a transient drop, have been observed. Skin reactions like rashes have also been reported rarely. More serious side effects, though infrequent, could involve effects on heart rhythm, particularly in susceptible individuals. (DrugBank, MedlinePlus)
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Vinpocetine should be used with caution in individuals with pre-existing heart conditions, particularly those with arrhythmias or a history of heart attack, due to its potential cardiovascular effects. Individuals with bleeding disorders or those undergoing surgery should also exercise caution, as vinpocetine may have mild anti-platelet effects. It is not recommended for use during pregnancy or breastfeeding, as safety has not been established. Patients with kidney or liver impairment should consult a healthcare professional before use. (MedlinePlus, DrugBank)
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Vinpocetine is contraindicated in individuals with known hypersensitivity to the compound or its excipients. It should not be used in cases of acute cerebral hemorrhage due to its vasodilator properties. Given its potential for cardiovascular effects, it is generally advised against in individuals with severe cardiac arrhythmias or conditions that could be exacerbated by changes in blood pressure or heart rate. Pregnancy and lactation are also contraindications due to insufficient safety data. (DrugBank)
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Vinpocetine may interact with certain medications, potentially increasing the risk of adverse effects. It should not be combined with anticoagulants (blood thinners) such as warfarin, aspirin, or clopidogrel, as this may increase the risk of bleeding due to vinpocetine's mild anti-platelet effects. Individuals taking medications for blood pressure should use vinpocetine with caution, as it may cause a further decrease in blood pressure. Similarly, caution is advised when combining it with drugs that affect heart rhythm, such as antiarrhythmics, due to potential additive effects. Discuss all current medications with a healthcare professional before taking vinpocetine. (MedlinePlus)
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Vinpocetine is typically taken in the morning. For optimal absorption, it is generally recommended to take it with food. The half-life of vinpocetine in the body is approximately 3 hours, which guides its dosing frequency in clinical use. Individual needs vary — talk to a licensed clinician.
Source for this section: Sources for When should you take Vinpocetine?: Jumps to this entry in the sources and references list at the end of the page.
Put it into practice
Reading about Vinpocetine is the first step — DoseRoutine helps you act on it. These free tools turn what you just learned into a routine.
What interacts with Vinpocetine?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any glp1 + supplement | Note | Category ruleConfidence: theoretical | GLP-1 medications slow stomach emptying, changing how/when oral supplements absorb; rapid weight loss raises the importance of protein and micronutrients.Source pending | Time oral supplements when nausea is lowest; prioritize protein and micronutrients; discuss with your provider. |
| Any supplement + medication | Note | Category ruleConfidence: theoretical | Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).Source pending | Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist. |
Frequently asked questions about Vinpocetine
Vinpocetine is a synthetic derivative of apovincamine, an alkaloid originally found in the *Vinca minor* plant, also known as the common periwinkle.
Vinpocetine is believed to support brain health primarily by enhancing cerebral blood flow, through its action as a PDE1 inhibitor, and by offering neuroprotective properties, potentially by modulating ion channels and acting as an antioxidant.
Yes, vinpocetine has the potential to affect blood pressure, sometimes causing a transient decrease. Individuals with pre-existing blood pressure issues or those on blood pressure medication should be cautious and consult a clinician.
No, vinpocetine is not considered safe for everyone. It is generally contraindicated during pregnancy and lactation, for individuals with certain heart conditions, acute cerebral hemorrhage, or those taking blood-thinning medications. Always consult a healthcare professional.
Vinpocetine is a supplement, and interactions are possible with prescriptions, hormones, peptides and other supplements in the same routine. Because Vinpocetine is usually taken in the morning, most avoidable conflicts come from what else lands in that same window. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Vinpocetine with no sign-up.
Vinpocetine is typically taken in the morning. Published protocols usually have it taken with food. Ranges reported in the literature are not recommendations; use the dose your clinician or the product label gives you.
Combining a supplement like Vinpocetine with TRT is usually a question of labs rather than a blanket yes or no: the ester, injection interval and any aromatase inhibitor all change the answer. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Each peptide class carries its own profile against Vinpocetine: a healing peptide raises different questions than a GLP-1 agonist or a growth-hormone secretagogue. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
Published frequency for Vinpocetine varies by protocol and formulation, so the label or prescription is what sets it. It is typically taken in the morning. Most protocols have it taken with food. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
The effect of a missed dose of Vinpocetine depends on the protocol and formulation you are on. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For Vinpocetine the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Cochrane review covered trials using roughly 30 mg/day oral vinpocetine; other clinical and cognitive-enhancer literature cites doses in a similar 15–60 mg/day range. Route reported: Oral, as tablets in the trials reviewed. Frequency reported: Divided into multiple daily doses (typically two to three times daily) in the reviewed trials. These are amounts documented in the cited studies and labels for Vinpocetine — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
Which studies looked at Vinpocetine?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Vinpocetine, cognition, and epilepsy(opens PubMed in a new tab)Epilepsy Behav · 2021 · PMID 33957389 · https://pubmed.ncbi.nlm.nih.gov/33957389/
- 2.An update on vinpocetine: New discoveries and clinical implications(opens PubMed in a new tab)Eur J Pharmacol · 2018 · PMID 29183836 · https://pubmed.ncbi.nlm.nih.gov/29183836/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 443955(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/443955
Verify at
Publisher search links for Vinpocetine. These are places to check the information — they are not citations, so they are not numbered.
- Cochrane Library(publisher search, opens in a new tab)Cochrane · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- Examine.com(publisher search, opens in a new tab)Examine.com · publisher search
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Vinpocetine?
Plain-text summary, safe to quote verbatim:
Vinpocetine is a synthetic ethyl ester of apovincamine, an alkaloid derived from the Vinca minor plant, commonly known as periwinkle. It was first synthesized in the late 1960s. Research on Vinpocetine focuses on cognition and mood. It is typically taken in the morning.
Source: DoseRoutine — https://doseroutine.com/library/vinpocetine
Vinpocetine cheat sheet
DoseRoutine cheat sheet · Supplement
Vinpocetine
Vinpocetine is a synthetic ethyl ester of apovincamine, an alkaloid derived from the Vinca minor plant, commonly known as periwinkle. It was first synthesized in the late 1960s.
Evidence
Strong
1 human randomized trial published.
Studied range
Cochrane review covered trials using roughly 30 mg/day oral vinpocetine; other clinical and cognitive-enhancer literature cites doses in a similar 15–60 mg/day range
Route
Oral, as tablets in the trials reviewed
Frequency studied
Divided into multiple daily doses (typically two to three times daily) in the reviewed trials
Half-life
Not consistently reported across the cited sources
Timing
in the morning
With food
with food
Not FDA-approvedOTC supplementNot FDA-approved as a drug in the US; marketed domestically as a dietary supplement, while it is a prescription medicine in several other countriesThe Cochrane review found the evidence base too limited in size and quality to draw firm conclusions about efficacy for dementia or cognitive impairmentBrain
Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/vinpocetine
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Vinpocetine — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/vinpocetine
What compounds are similar to Vinpocetine?
Others in the supplement category or studied for the same goals.
Which goals is Vinpocetine used for?
Other compounds studied for the same benefits as Vinpocetine.
Continue exploring
See every compound DoseRoutine catalogs for these goals.